logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Cancer and Palliative Care

Results

Drugs

November 2019

Atezolizumab for muscle-invasive urothelial carcinoma –adjuvant

Atezolizumab is currently in clinical development for the treatment of patients muscle-invasive urothelial cancer (MIUC) including muscle-invasive bladder cancer (MIBC) and upper tract urothelial cancer (UTUC) patients who are at high risk following resection. MIBC is a cancer that spreads into the thick muscle deep in the bladder wall. MIBC starts in the inner bladder layer and then grows in the deep muscle. While UTUC can arise along any part of the urinary tract lined with urothelium with the majority of cases in the lower tract and rest in the upper tract. Over time the tumour may grow outside the bladder into tissues close by and then may spread to lymph nodes, the lungs, the liver and other parts of the body. The current standard care of treatment includes a surgery which might not be adequate and some patients might be at high risk for recurrence.

Drugs

November 2019

Avelumab in addition to best supportive care for locally advanced or metastatic urothelial cancer

Avelumab in addition to best supportive care (BSC) is in clinical development for the maintenance treatments of adults with locally advanced or metastatic urothelial cancer that did not progress on or following completion of first-line chemotherapy. Urothelial cancer occurs on the lining of the bladder and other parts of the urinary system. In advanced urothelial cancer, cancer has grown into deeper layers including connective tissue or muscle. Metastatic urothelial cancer is when the cancer has spread to other parts of the body, such as the liver or bones. Urothelial cancer usually occurs in patients aged 60 years and older, where patients may have other medical conditions or are not fit enough to be given certain treatments.

Drugs

October 2019

Nivolumab in combination with cisplatin and fluorouracil for oesophageal cancer – first-line

Nivolumab in combination with cisplatin and fluorouracil is in clinical development for patients with unresectable, advanced, recurrent or metastatic oesophageal squamous cell cancer cell carcinoma. Advanced oesophageal cancer begins in the food pipe and spreads to other parts of the body. Squamous cell cancers develop from the cells that make up the inner lining of the oesophagus. Symptoms include difficulty swallowing, persistent acid indigestion or heartburn, weight loss, pain in the throat, and chronic cough. Lifestyle factors are attributed to most oesophageal cancers, including smoking and being overweight.

Drugs

October 2019

Olaparib monotherapy for BRCA-mutated platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer

Olaparib is a medicinal product currently in development for the treatment of Breast Cancer Gene (BRCA)-mutated relapsed ovarian, fallopian tube or primary peritoneal cancer in patients who have received at least 2 prior platinum treatments and have progressed at least 6 months after their last platinum treatment. Ovarian cancer includes a group of tumours that arise from diverse types of tissue contained in the ovary and can often spread from the ovary to any surface within the abdominal cavity including the fallopian tubes and peritoneal cavity.

Drugs

October 2019

Pertuzumab and trastuzumab (fixed-dose combination) in addition to chemotherapy for breast cancer

Pertuzumab/trastuzumab (fixed-dose combination (FDC) in addition to chemotherapy is in clinical development as a subcutaneous formulation (SC) for the adjuvant treatment of adults with the human epidermal growth factor receptor 2 (HER2) positive early and metastatic breast cancer. HER2 positive breast cancer is a subtype in which the HER2 receptor is over expressed on the cell surface. HER2 promotes the growth of cancer cells and this breast cancer subtype tends to be more aggressive than other types. Metastatic breast cancer is when cancer has spread beyond the breast and nearby lymph nodes to other organs in the body. Treatment of the disease often involves the use of anti-HER2 therapies, chemotherapy or a combination of both.

Drugs

October 2019

Durvalumab in combination with tremelimumab for unresectable hepatocellular carcinoma – first line

Durvalumab in combination with tremelimumab is in clinical development for patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer that occurs mainly in patients with underlying chronic liver disease and cirrhosis. Unresectable HCC occurs when the cancer has spread to lymph nodes or to other organs and cannot be treated by surgery. Unresectable HCC is often diagnosed late in life and has a poor prognosis. It is a debilitating condition with many distressing symptoms, including pain, digestive problems and weight loss. The current standard of care can only slow the progression of the cancer and extend survival.

Drugs

October 2019

Trastuzumab emtansine in combination with pertuzumab for HER2-positive early breast cancer – adjuvant therapy

Trastuzumab emtansine consists of an anti-HER2 therapy (trastuzumab) and a chemotherapy agent (emtansine or DM1) combined together as an antibody-drug conjugate. Trastuzumab specifically binds to cancer cells that are HER2-positive which provides a targeted delivery of the cytotoxic DM1 inside cancer cells, potentially limiting damage to healthy tissue. Pertuzumab, is designed to attach to HER2, and stop HER2 producing signals that cause the cancer cells to grow. The combination is thought to provide a more comprehensive, dual blockade of HER pathways and prevent tumour cell growth and survival, and if licenced, will offer an additional adjuvant treatment option for patients with HER2- positive early breast cancer.

Drugs

October 2019

Nivolumab for platinum-resistant advanced or recurrent ovarian cancer

Nivolumab is in development for the treatment of platinum-resistant, advanced or recurrent ovarian cancer. Ovarian cancer is one of the most common types of cancer in women. The symptoms of the disease are vague, including loss of appetite and tummy pain. This can mean that the cancer is often diagnosed when the disease is advanced and more difficult to treat. Most patients have the cancer removed by surgery and also receive chemotherapy, which usually includes platinum-based drugs. However, ovarian cancer often recurs and the platinum-based chemotherapy drugs may be less effective at treating this recurrence. If the cancer recurs within 6 months of the previous treatment, and platinum-based chemotherapy does not work, the disease is called ‘platinum resistant’.

Drugs

September 2019

Carfilzomib in addition to daratumumab and dexamethasone for relapsed and/or refractory multiple myeloma

Carfilzomib, is a proteasome inhibitor. Proteasome is a system within the cells that breaks down proteins that are no longer needed. Cancer cells have an increased need to produce and break down proteins as they multiply rapidly. When carfilzomib stops the proteasome from breaking down proteins in the cancer cells, the proteins build up and cause the cells to die, slowing down the growth of the cancer. The addition of daratumumab and dexamethansone to carfilzomib may potentially improve outcomes and reduce side effects in patients with relapsed and/or refractory MM who have received prior therapies.

Drugs

September 2019

Atezolizumab in addition to paclitaxel for inoperable, locally advanced or metastatic triple negative breast cancer – first-line

Atezolizumab as an intravenous infusion in combination with an intravenous infusion of paclitaxel (chemotherapy) is in clinical development for the first-line treatment of locally advanced or metastatic triple-negative breast cancer (TNBC). TNBC is a type of breast cancer in which the cancer cells do not express receptors for oestrogen or progesterone or HER2 protein. Treatment of TNBC is challenging because of a lack of targeted therapy, aggressive disease course, and relatively poor prognosis. Treatment is usually through a combination of surgery, radiotherapy, and chemotherapy.

Get Alerts